Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.

<h4>Background</h4>Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, making it more amenable to combination therapy.<h4>Met...

Full description

Saved in:
Bibliographic Details
Main Authors: Graham H Jackson, Charlotte Pawlyn, David A Cairns, Ruth M de Tute, Anna Hockaday, Corinne Collett, John R Jones, Bhuvan Kishore, Mamta Garg, Cathy D Williams, Kamaraj Karunanithi, Jindriska Lindsay, Alberto Rocci, John A Snowden, Matthew W Jenner, Gordon Cook, Nigel H Russell, Mark T Drayson, Walter M Gregory, Martin F Kaiser, Roger G Owen, Faith E Davies, Gareth J Morgan, UK NCRI Haemato-oncology Clinical Studies Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS Medicine
Online Access:https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003454&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003454&type=printable

Similar Items